In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, describes how PBMs financially benefit from generics, and why a completely open generic market powered by cash would be beneficial.
The latest news for pharma industry insiders.
Why meaningful content must meet the right audience.
In the fourth part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, comments on health policy developments that the pharma supply chain should be aware of.
The latest news for pharma industry insiders.
After an initial 30-day pause, the US president plans to re-enact the import taxes on the nation’s trading partners—while also doubling the 10% tariff on China.
Tracy Lopez uncovers the fundamentals pertaining to third-party logistics providers.
In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, describes how the tariffs can affect price or competition within the branded drug space.
The latest news for pharma industry insiders.
The news comes amid the possibility that President Trump imposes a 25% tariff on pharmaceuticals, which could encourage manufacturers to begin reshoring their services.
In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, details the factors that could makes the generic drug market susceptible to supply chain disruptions.
The presidential action follows up on a 2019 final rule aimed at empowering patients and boosting competition among hospitals, group health plans, and health insurance issuers in both individual and group markets.
In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics at USC, outlines how the tax on goods coming from China and potential 25% tariff on pharmaceuticals could influence generic drug prices.
The latest news for pharma industry insiders.
Patients who utilize the self-pay pharmacy will also be receiving savings on select sizes.
In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Tom Dorsett, CEO, RazorMetrics, comments on why he believes polypharmacy is an overlooked driver of unnecessary spending and adverse health outcomes.
The latest news for pharma industry insiders.
The injection for the treatment of psoriatic arthritis—among other indications—is a biosimilar to Stelara.
In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Tom Dorsett, CEO, RazorMetrics, explains the concept of polypharmacy, including how prominent it is in the United States today.
The latest news for pharma industry insiders.
James D. Chambers, PhD, MPharm, MSc, professor of medicine at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, dives into why biosimilars contribute to a reduction in cost and increase in patient access, while highlighting challenges to adoption.
In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of sales, life sciences, Loftware, comments on other concepts that are powering the company’s 2025 Supply Chain Trends Report, and how they could possibly change in 2026.
The latest news for pharma industry insiders.
FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of sales, life sciences, Loftware, discusses why the demand for supply chain transparency is continuing to gain momentum, while also explaining the role that track-and-trace initiatives are playing in that effort.
The latest news for pharma industry insiders.
The timing for the potential tax is yet to be determined, as the industry awaits to see the impact it could bring.
The latest news for pharma industry insiders.
A qualitative study examines how Medicaid telehealth reimbursement policies affect staffing and patient-centered care.
